Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | VERT-002 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on VERT-002, a putative monoclonal antibody targeting MET (Nov 2024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| VERT-002 | VERT002|VERT 002|PFL-002|PFL002|PFL 002 | MET Antibody 37 | Limited information is currently available on VERT-002, a putative monoclonal antibody targeting MET (Nov 2024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06669117 | Phase Ib/II | VERT-002 | FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations | Recruiting | USA | NLD | ITA | FRA | ESP | DEU | BEL | 2 |